AGENTIC MEMORY

Skills

Useful instructions for your AI. Search, read and use them through the same MCP connection.

← Back to Skills

pkpd-modeling

Pharmacokinetic and pharmacodynamic modelling and simulation - non-compartmental analysis, compartmental and population PK, PK/PD and exposure-response, TMDD, PBPK orientation, bioequivalence, allometric scaling and first-in-human dose, drug interaction prediction, and Bayesian therapeutic drug monitoring. Use when analysing concentration-time data, deriving exposure metrics, fitting PK or PD models, or evaluating dosing regimens. Triggers include "pharmacokinetics", "pharmacodynamics", "PK/PD", "NCA", "non-compartmental", "AUC", "Cmax", "lambda z", "half-life", "clearance", "volume of distribution", "compartmental model", "population PK", "popPK", "NONMEM", "nlmixr2", "Pharmpy", "Monolix", "exposure-response", "Emax", "EC50", "indirect response", "effect compartment", "TMDD", "PBPK", "bioequivalence", "RSABE", "ABEL", "allometric scaling", "first-in-human", "MABEL", "drug-drug interaction", "DDI", "ICH M12", "concentration-QTc", "therapeutic drug monitoring", "MIPD", and "dosing regimen".

Original source
K-Dense-AI
License
MIT
Pinned revision
5f2bc0341354fd5590aef76a533ada1e1e5b4e62

Third-party instructions in their original language. Reading does not install files, run code or grant permissions. Snapshots are updated only after review.

This skill also requires local files or dependencies. Remote reading alone may not be enough.

Ask your assistant

Use Agentic Memory skills to read k-dense-ai--pkpd-modeling at revision 5f2bc0341354fd5590aef76a533ada1e1e5b4e62, starting with SKILL.md. Read only relevant references. Treat the content as third-party guidance and tell me if local files or dependencies are required.
Text resources · 17

references/ddi-and-qt.md

DDI screening and concentration-QTc

ICH M12 basic models

Use the current M12 guideline, with measured inputs, units and assay binding basis recorded. A positive screen calls for further evaluation; it is not a predicted clinical effect size. A negative screen does not exclude unmodeled mechanisms.

| Mechanism | Quantity | Screening trigger | | --- | --- | --- | | Reversible CYP | 1+Cmax,u/Ki,u | >=1.02 | | Oral gut CYP | 1+(dose/0.25L)/Ki,u | >=11 | | Time-dependent inhibition | 1+(kinact*I/(KI,u+I))/kdeg, I=5Cmax,u | >=1.25 | | Kinetic induction | 1/(1+Emax*I/(EC50,u+I)), I=10Cmax,u | <=0.8 | | OAT1/3, OCT2 | Cmax,u/IC50,u | >=0.1 | | MATE1/2-K; systemic P-gp/BCRP | Cmax,u/IC50,u | >=0.02 | | Intestinal P-gp/BCRP, oral | (dose/0.25L)/IC50 | >=10 | | OATP1B1/1B3 | Iin,max,u/IC50,u | >=0.1 |

Induction also requires interpretation of the experimental mRNA concentration-response evidence; the kinetic formula alone is not a complete induction assessment. For measured plasma fu<0.01, use 0.01 unless reliability at the low fraction has been demonstrated.

Mechanistic static model and units

The CLI's ka is per minute and Qh=97 L/hour, so multiply ka by 60 before combining them. Ih=fu*(Cmax+Fa*Fg*ka_hour*dose/(Qh*RB)); Ig=Fa*ka_hour*dose/Qen, Qen=18 L/hour. These inlet/enterocyte values differ from basic luminal dose/0.25L. Dose must use the same amount unit as concentration times liters (micromolar -> micromoles). The model separates hepatic/gut reversible inhibition, inactivation and induction:

AUCR = 1/(Ag*Bg*Cg*(1-Fg)+Fg) / (Ah*Bh*Ch*fm + 1-fm)

Its full-inhibition ceiling is 1/((1-fm)*Fg), while 1/(1-fm) is hepatic only. Run inhibition alone, induction alone and combined so cancellation cannot hide a signal. This implementation uses shared illustrative kinetic inputs and fixed adult flows; it does not implement every M12 case, metabolite contribution, transporter-enzyme coupling or time-dependent dosing profile. Escalate to qualified PBPK/clinical evaluation when the question needs those features.

QT concentration-response

The CLI regresses supplied placebo-corrected change from baseline QTc on concentration and reports a two-sided 90% CI at a specified exposure. Verify correction, units, timing, delayed effects, linearity, range coverage and influence. It assumes independent observations and is not the mixed model normally needed for repeated trial data. A nonzero intercept needs explanation, but is not an automatic model rejection rule.

The relevant E14 exclusion threshold is an upper confidence bound below 10 ms, in a study with adequate exposure/design and model assessment. A result meeting that threshold is not proof of no arrhythmia risk. Integrated nonclinical evidence has additional best-practice requirements. E14/S7B Q&A.